Table 1.
Clinical characteristics of study population
| Baseline | After 2 weeks | P value | |
|---|---|---|---|
| N (male/female) | 47 (34/13) | ||
| Age (years) | 56.6 ± 13.0 | ||
| Height (cm) | 165.3 ± 9.5 | ||
| Weight (Kg) | 75.3 ± 19.6 | 73.7 ± 18.6 | 2.11 × 10–7 |
| BMI | 27.3 ± 5.6 | 26.8 ± 5.3 | 8.05 × 10–8 |
| Body fat mass (%) | 28.8 ± 9.5 | 28.8 ± 9.2 | 0.995 |
| Body fat weight (kg) | 22.5 ± 11.3 | 22.0 ± 10.8 | 0.11 |
| Lean body weight (kg) | 52.8 ± 12.3 | 51.7 ± 11.3 | 0.001 |
| Visceral fat area (cm2) | 104.0 ± 52.5 | 96.3 ± 46.2 | 0.009 |
| FPG (mg/dl) | 172.6 ± 53.2 | 111.1 ± 17.2 | 9.57 × 10–11 |
| HbA1c (%) | 10.2 ± 2.4 | ||
| Fasting IRI (μU/ml) | 10.4 ± 7.3*** | 9.7 ± 5.2* | 0.006 |
| Fasting C-peptide (ng/ml) | 2.2 ± 1.3 | 1.8 ± 1.2** | 0.002 |
| HOMA-IR | 4.3 ± 3.6*** | 2.8 ± 1.8* | 0.0002 |
| Diabetic therapy | |||
| DP/BG/TZ/SU/GL/AG/SG | 29/20/1/9/1/7/0 | 32/27/11/4/7/10/7 | |
| INS/GLP-1/NONE | 8/1/6 | 22/3/2 | |
Data are mean ± SD
DP, DPP-4 inhibitors; BG, biguanide; TZ, thiazolidine; SU, sulfonylureas; GL, glinides; AG, α glucosidase inhibitors; SG, SGLT-2 inhibitors; INS, insulin; GLP-1, GLP-1 receptor agonist
*n = 18
**n = 44
***n = 36